-
Focus on win-win: BIPS 2nd Global Biomedical Innovation Pioneer China Summit 2022
Time of Update: 2022-05-02
Conference introduction▪ The "2nd Global Biopharma Innovation Pioneer China Summit 2022" hosted by Cover Media Group will be held in Shanghai from May 26th to 27th, 2022 . ▪ This summit includes two
-
Takeda China's First Rare Genetic and Blood Disorders Summit Successfully Held
Time of Update: 2022-05-02
The theme aims to create a national academic exchange platform, and join hands with relevant people from all walks of life such as clinical medicine, pharmacology, policy experts, and patient organization representatives to discuss core issues such as cutting-edge treatment plans for rare diseases, diagnosis and treatment system construction, and patient disease management.
-
[Live Preview] System Verification of Purified Water Equipment
Time of Update: 2022-05-02
These challenges are yet to be solved [ Information Search ] [ Add to Favorites ] [ Tell a Friend ] [ Print This Article ] [ Close Window ] Similar Information +~(-new Date()/36e5)]; Keywords: [Live Preview] System Verification of Purified Water Equipment, Purified Water Equipment Previous: The domestic pharmaceutical equipment market has a blue ocean of 100 billion yuan?
-
[Early Bird Countdown 1 Day] BioCon-Antibody's blockbuster debut agenda is open, from source to CMC to clinical transformation, accelerating FIC drug development
Time of Update: 2022-05-02
The 9th International Biopharmaceutical Conference Series-Antibody Forum was specially invited Dr. Dimiter S. Dimitrov, Director of the Antibody Center, University of Pittsburgh School of Medicine,
-
Keeping up with the pace of scientific and technological development, the 19th Nanjing Scientific Instrument and Laboratory Equipment Exhibition in 2022 has entered a new historical starting point
Time of Update: 2022-05-02
Since the "Thirteenth Five-Year Plan", under the strong leadership of the Jiangsu Provincial Party Committee and the Provincial Government, the education system in the province has fully implemented X
-
Phase I clinical trial of three-drug combination anti-CD40, anti-CTLA-4 and anti-PD-1 monoclonal antibody was approved by the National Medical Products Administration of China
Time of Update: 2022-05-02
NMPA Approves Euho Pharma to Conduct a Phase I International Multicenter Clinical Research Trial in China: Safety, Tolerability and Pharmacokinetics of a Combination of YH003, YH001 and Pembrolizumab in Subjects with Advanced Solid Tumors A multicenter, open-label, phase I dose-escalation study of the drug (protocol number: YH003005) .
-
China's first original PARP inhibitor fluzoparib medical insurance market meeting held
Time of Update: 2022-05-02
Ai Ruiyi (fluzoparib) medical insurance listing will be linked online and offline venues At the meeting, experts discussed the challenges faced by ovarian cancer in China, the research layout of fluzoparib and the latest research progress .
-
Registration for the First Plant-Based Food Innovation Competition (China) officially opened
Time of Update: 2022-05-02
24, 2022 /PRNewswire/ -- Big Idea Ventures, the world's leading incubation accelerator for early-stage alternative protein investment companies, will cooperate with China Chamber of Commerce for Import and Export of Foodstuffs, Native Produce and Animal Products, China Plant-based Food Application Promotion Alliance, Shanghai Bohua International Exhibition Co.
-
【Topic】Fluidigm multi-omics solution to discuss infectious disease research with you
Time of Update: 2022-05-02
Recently, we have specially opened the application topic " Fluidigm Multi-omics Solutions - Helping Advance Infectious Disease Research ", to summarize the application and prospect of Fluidigm's core products and technologies in infectious disease research in recent years .
-
Yuyue Medical has landed in La Liga, taking globalization as a new starting point and actively integrating into the global innovation network
Time of Update: 2022-05-02
prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.
Spanish doctors test and approve the clinical role of Yuyue Medical's non-invasive ventilator In a global epidemic, major countries are responsible .
-
BeiGene Announces that Baiyueze(R) (zanubrutinib) has been accepted for marketing authorization by the European Medicines Agency for the treatment of chronic lymphocytic leukemia and marginal zone lymphoma
Time of Update: 2022-05-02
The company announced today that the European Medicines Agency (EMA) has accepted two trials for the BTK inhibitor Baiyueze® (zanubrutinib) for the treatment of patients with chronic lymphocytic leukemia (CLL) and patients with marginal zone lymphoma (MZL).
-
Biosin Biotech Appoints Mr. Joel Edwards as Chief Commercial Officer
Time of Update: 2022-05-02
prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
Joel Edwards has joined the company's management team at a critical stage in our continued expansion of global business development and alliance cooperation," said Dr.
-
BeiGene Announces that Baiyueze(R) (zanubrutinib) has been accepted by the U.S. Food and Drug Administration for a New Indication Marketing Authorization Application for the Treatment of Chronic Lymphocytic Leukemia
Time of Update: 2022-05-02
62em; font-family:"Arial"; color:black; margin:0in; } </>The filing is based on two global Phase 3 trials of Baiyueze® in chronic lymphocytic leukemia , both of which covered treatment-naïve and relapsed / refractory patient populationsFDA target date for decision on this application under the Prescription Drug Filer Fees Act is October 22 , 2022BEIJING, China and CAMBRIDGE, Mass.
-
Innovent Announces First Clinical Patient Dosing of Universal "Modular" CAR-T Cell Drug IBI345
Time of Update: 2022-05-02
The principal investigator of the study, Secretary of the Party Committee of the First Affiliated Hospital of Soochow University, Chief Physician of the Department of Gastroenterology, and Professor Chen Weichang pointed out: "Solid tumors such as gastric cancer and pancreatic cancer are malignant tumors with high incidence in the world, and Claudin18.
-
Beihai Kangcheng CAN108 Maralixibat Oral Liquid was approved for "first trial" in Boao Lecheng International Medical Tourism Pilot Zone
Time of Update: 2022-05-02
Beihai Kangcheng has an exclusive license to develop and commercialize CAN108 in Greater China for three rare liver disease indications: Alajeri syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC) and biliary atresia ( BA) .
-
Keji Pharmaceutical's first overseas cGMP production plant starts operation in the United States, accelerating its global layout
Time of Update: 2022-05-02
HK), a company primarily focused on the treatment of hematological malignancies and solid tumors An innovative CAR-T cell therapy company, announced today that the cGMP production plant (hereinafter referred to as the "RTP production plant") built by the company's American company CARsgen Therapeutics Corporation in the Research Triangle Park (RTP) area of North Carolina, USA has passed the official inspection of the local government .
-
WuXi Biologics has won six core awards of "CMO Leading Enterprise Award" for five consecutive years
Time of Update: 2022-05-01
HK), a global CRDMO service company, announced today that the company has once again won the 2022 "CMO Leading Enterprise Award" six core awards -- The "Capability", "Compatibility", "Professional", "Reliability", "Quality" and "Service" awards are also the fifth consecutive year that WuXi Biologics has received this honor .
-
Tianjing Biotech's new dual-antibody TJ-CD4B for the treatment of gastric cancer received FDA orphan drug designation
Time of Update: 2022-05-01
The biopharmaceutical company is committed to the target biological research of innovative biopharmaceuticals, antibody technology, clinical development and product commercialization in China and the United States, and provides new and effective treatment methods for the urgently needed cancer treatment field worldwide .
-
Bio-Site and Nanjing Chia Tai Tianqing signed a fully human antibody cooperation development agreement
Time of Update: 2022-05-01
We hope that through this cooperation, Bio-Situ's large-scale new drug R&D platform and Nanjing Chia Tai Tianqing in process development and In terms of industrialization, we will achieve strong alliances, rapidly promote the entry of new drugs into the clinic, and provide effective and safe innovative antibody drugs to protect people's health .
-
Maiwei Bio's first drug, adalimumab, was approved for marketing
Time of Update: 2022-05-01
prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
Maiwei Bio has established a market-leading, medical-driven, access The first integrated professional academic promotion and marketing team, based in China and looking at the world .
